In:
Cancer Science, Wiley, Vol. 105, No. 4 ( 2014-04), p. 437-444
Abstract:
BACH 2, a B cell‐specific transcriptional repressor, plays a significant role in B cell maturation. Despite a number of previous studies, the clinicopathological significance of BACH 2 expression in diffuse large B cell lymphoma ( DLBCL ) remains to be established. The present study was performed to validate the significance of BACH 2 expression as a predictor of prognosis in DLBCL . A total of 94 DLBCL cases were included in the present study. All were diagnosed between 2008 and 2011, and thorough clinical and pathological investigations were possible, including immunohistochemical analysis of BACH 2. Eighteen cases were selected by positive MYC gene alteration ( MYC + group) according to cytogenetic study. The remaining 76 cases were subclassified into germinal center B cell phenotype ( GCB group, 38 cases) or non‐ GCB phenotype (non‐ GCB group, 38 cases). There were no significant differences between the two groups with regard to clinical characteristics and outcomes. In the GCB group, 21 cases were judged to have high BACH 2 expression, with 19 cases in the non‐ GCB group. In cases with high BACH 2 expression in GCB and non‐ GCB groups, the 3‐year overall survival ( OS ) rate was significantly shorter than that with low expression (71.7% vs 91.3%, P = 0.0256). In the MYC + group, 15 cases had high BACH 2 expression levels. Although overall the MYC + group showed short survival time (3‐year OS 35.0%), 3 out of 4 cases with low BACH 2 expression are alive without disease relapse at the time of publication of this paper. In conclusion, BACH 2 expression level is a promising predictor of prognosis for DLBCL .
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2014.105.issue-4
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Permalink
